Back to UBS Group AG UBS Group AG

AVTXAVTX
Showing 8 of 11 quarters

Position history for UBS Group AGUBS Group AG's holdings in AVALO THERAPEUTICS INC

UBS Group AG holds 1.2M shares of AVTX (AVALO THERAPEUTICS INC), worth $22.3M as of 2026-Q2. The position was increased (+5.9% shares). AVTX represents 0.0% of UBS Group AG's portfolio.

Current Value

$22.3M

Current Shares

1.2M

Total Value Change

+$22.3M

Total Shares Change

+1.2M

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
1.2M
+5.9%
$22.3M0.0%$18.48
30
2026-Q1
Increased
1.1M
+139.0%
$17M0.0%$18.85
46
2025-Q4
Increased
477,816
+956.9%
$8.7M0.0%$17.81
44
2025-Q3
Decreased
45,208
-46.0%
$574,5940.0%$13.02
0
2025-Q2
Decreased
83,724
-15.4%
$417,7830.0%$4.78
0
2025-Q1
Increased
98,951
+0.4%
$792,5980.0%$8.46
25
2024-Q4
Increased
98,519
+1506.1%
$731,9960.0%$7.80
40
2024-Q3
Increased
6,134
+71.2%
$58,2730.0%$9.40
21

Other major holders of AVTX: FMR LLC, BlackRock, Inc., STATE STREET CORP, FARALLON CAPITAL MANAGEMENT, L.L.C., Point72 Asset Management, L.P.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used